R&D channel feed

Vivek Ra­maswamy’s Meta­vant hits a brick wall, aban­don­ing a lead pro­gram for di­a­betes. And there’s noth­ing vis­i­ble left to see here

5 years ago
People

Look­ing for leg up in he­mo­phil­ia B gene ther­a­py race, uniQure flash­es da­ta that helped lead to $2B CSL deal

5 years ago
Cell/Gene Tx

Gilead touts piv­otal da­ta for new kind of HIV ther­a­py, open­ing to­wards large po­ten­tial mar­ket

5 years ago

Bris­tol My­ers Squibb Foun­da­tion launch­es pro­gram to tack­le di­ver­si­ty prob­lem in clin­i­cal tri­als

5 years ago
Pharma

GSK and Vi­iV score break­through ther­a­py des­ig­na­tion in HIV pre­ven­tion, as Tru­va­da show­down draws near­er

5 years ago
FDA+

BeiGene beefs up PD-1 da­ta with pos­i­tive PhI­II re­sults for tislelizum­ab, this time in metasta­t­ic NSCLC

5 years ago

The pri­ma­ry failed. The key sec­ondary failed. But this biotech still be­lieves it can win an FDA OK in ALS

5 years ago

Alk­er­mes is hand­ed a CRL for ‘3831, mark­ing an­oth­er set­back on the R&D front

5 years ago
FDA+

Fa­heem Has­nain is go­ing back to run­ning a biotech start­up. And he has his work cut out for him

5 years ago
People

Mod­er­na says its vac­cine is 94.5% ef­fec­tive at pre­vent­ing Covid-19, ap­pears to stop se­vere dis­ease

5 years ago
Coronavirus

Cy­to­ki­net­ics cheers a PhI­II read­out for their heart drug de­vel­oped with Am­gen, but an­a­lysts and in­vestors aren't join­ing the par­ty

5 years ago

Short­age of mon­keys slowed down Eli Lil­ly's Covid-19 an­ti­body part­ner. And it's a prob­lem for every­one

5 years ago
China
Coronavirus

Bio­Marin CEO Bi­en­aimé beats a re­treat from Eu­rope, yank­ing their ap­pli­ca­tion for he­mo­phil­ia A gene ther­a­py

5 years ago
FDA+

In­ter­fer­on be­ta-1a can­di­date for COPD ad­vances to PhI­II to test its po­ten­tial against Covid-19

5 years ago
Coronavirus

Pfiz­er’s cel­e­brat­ed Covid-19 vac­cine freezes many peo­ple out — but a ri­val mR­NA team says they thawed out a so­lu­tion

5 years ago

Jim Wil­son of­fers a safer so­lu­tion to some of the in­dus­try's gene ther­a­py woes

5 years ago
Cell/Gene Tx

Pfiz­er, still chas­ing Dupix­ent, re­leas­es fifth round of da­ta for eczema JAK in­hibitor abroc­i­tinib

5 years ago

Top an­a­lyst sizes up wind­fall bil­lions for Pfiz­er, Re­gen­eron and Eli Lil­ly in a big week for the Covid-19 R&D race

5 years ago

A can­cer vac­cine that might work? Mod­er­na posts 'promis­ing' ear­ly snap­shot for Mer­ck-part­nered pro­gram and raids Bris­tol My­ers for a new can­cer R&D chief

5 years ago

Five Prime claims a big win in topline da­ta for their come­back gas­tric can­cer drug as shares sky­rock­et

5 years ago

A few months af­ter emerg­ing from stealth, Prax­is is hand­ed a clin­i­cal hold for lead de­pres­sion drug

5 years ago
FDA+

As­traZeneca, Am­gen tout PhI­II win for 'break­through' asth­ma drug, check­ing a block­buster box that Dupix­ent did­n't

5 years ago

Mer­ck pulls the plug on a study eval­u­at­ing block­buster Keytru­da with Yer­voy for NSCLC

5 years ago

In an­oth­er win for mR­NA, Cure­Vac ex­ecs de­tail the new PhI read­out of their vac­cine da­ta and why they’re so pumped about it

5 years ago
First page Previous page 182183184185186187188 Next page Last page
A service from the Financial Times